Name | Title | Contact Details |
---|
GL Sciences is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are T-Bird Pharma Inc., a public company listed on the TSX-V. We are the parent company to Thunderbird Biomedical Inc. Thunderbird is a licensed medical marijuana producer operating within the parameters of Health Canada`s MMPR. Thunderbird obtained a medical marijuana license to undertake the production of medical marijuana in February 2014, being the fifth company in Canada to obtain such a license. T-Bird is the publicly traded parent company of Thunderbird.
Lafayette Drug Company, is a Lafayette, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients` needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.